

Cardisure Flavoured 1.25 mg Tablets for Dogs

Authorised

- Pimobendan

Product identification

Medicine name:

Cardisure Flavoured 1.25 mg Tablets for Dogs
Cardisure vet. 1,25 mg tableter til hund

Active substance:

Pimobendan

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Pimobendan
1.25 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Withdrawal period by route of administration:

Oral use:

-

Dog

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QC01CE90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Package description:

10 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)

10 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)

2 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)

2 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)

25 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)

25 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)

5 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)

5 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Eurovet Animal Health B.V.

Marketing authorisation date:

24/08/2011

Manufacturing sites for batch release:

Dales Pharmaceuticals Limited
Eurovet Animal Health B.V.

Responsible authority:

Norwegian Medical Products Agency

Authorisation number:

10-7667

Date of authorisation status change:

20/04/2016

Reference member state:

Netherlands

Procedure number:

NL/V/0280/001

Concerned member states:

Austria Belgium Denmark Finland France Germany Greece Ireland Italy
Luxembourg Norway Poland Portugal Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 16/06/2022

Download

107727 PAR.pdf

Source URL: <https://medicines.health.europa.eu/veterinary/600000036905>